On October 13, 2023, the Food and Drug Administration (FDA) announced that the guidance entitled “Prior Notice of Imported Food Questions and Answers (Edition 4): Guidance for Industry,” originally released as draft guidance on September 13, 2022, has been made final. FDA received no comments on the draft guidance, and as a result, is publishing the guidance as drafted, with minor editorial changes to improve clarity. By finalizing the Fourth Edition of this Guidance, FDA is formally replacing the Third Edition, dated June 2016.

The guidance document updates the previous version by making a clarification about submitting prior notice to FDA and including three additional questions.

  • The clarification to Question D.3.2 notes that prior notice must be submitted to FDA, and not both FDA and U.S. Customs and Border Protection (CBP). An authorized user of CBP’s ABI/AC/ITDS can submit prior notice to FDA through the ABI/ACE/IDTS interface or through FDA PNSI. Non-authorized users may arrange for prior notice submission by an authorized user or through FDA PNSI.
  • Question C.1.4 explains that food imported from a country with which FDA has a Systems Recognition Arrangement (SRA) or equivalence determination is not exempt from prior notice.
    • An SRA is a partnership between FDA and a foreign regulatory counterpart in which the agencies have concluded that they operate comparable regulatory programs for the purpose of sharing information and leveraging each other’s regulatory systems and activities to manage the safety of foods covered by the arrangement. The existence of an SRA with a country does not exempt food imported from that country from FDA prior notice requirements.
    • An equivalence determination is the process of determining whether a country’s food safety controls achieve at least the same level of public health protection as measures required by U.S. law. Because a final equivalence determination is limited to a specific set of food safety controls in a foreign country, imported foods must still comply with all applicable U.S. requirements not covered by the scope of FDA’s equivalence determination. Since FDA’s prior notice requirements fall outside the scope of an equivalence determination, imported foods covered by a final equivalence determination are not exempt from FDA prior notice requirements.
  • The other two questions, Questions E.1.6 and E.1.7, relate to FDA’s notice of a refusal under 801(m)(1) of the FD&C Act for inadequate prior notice or a hold under 801(l).
    • Question E.1.6 states that if FDA determines that a food will be held or released under 801(l) or 801(m)(1) when the food arrives at the border, the notification of prior notice refusals and holds will be communicated first to CBP and then be provided to the relevant party (i.e., the submitter or transmitter of prior notice) upon arrival of the article. This clarification is made to avoid creating an incentive for bad actors to attempt to reroute their entries for the purpose of evading FDA requirements and importing unsafe food if given advanced notice of a refusal or hold.
    • Question E.1.7 addresses the timeframe for making requests for FDA review of such a refusal or hold. The regulations state that the request must be submitted within 5 calendar days of the refusal or hold, and the Guidance clarifies that FDA considers the 5 calendar day clock to start at the time FDA provides notice of the refusal or hold to the relevant party who submitted the prior notice (i.e., submitter or transmitter) upon arrival of the article. Therefore, the time FDA provides notification of a refusal or hold, or a request for review is submitted, does not matter so long as it is within the 5 calendar day window.

Other helpful information and guidance on importing foods can be found on the FDA’s Importing Human Foods page. On September 29, 2023, the FDA posted a helpful video to this page about Importing FDA-Regulating Products: Human Foods. This video provides an overview of the steps to import, regulatory requirements, and tips for successful importation.

FDA will accept electronic or written comments on the updated guidance at any time. 

If you have any questions concerning the material discussed in this client alert, please contact the members of our Food, Beverage, and Dietary Supplements practice.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Miriam Guggenheim Miriam Guggenheim

Miriam Guggenheim, co-chair of Covington’s Food, Drug and Device Practice Group, assists a broad range of major food and dietary supplement companies in achieving their marketing goals while minimizing regulatory and litigation risks. She also helps clients successfully navigate crises such as recalls and…

Miriam Guggenheim, co-chair of Covington’s Food, Drug and Device Practice Group, assists a broad range of major food and dietary supplement companies in achieving their marketing goals while minimizing regulatory and litigation risks. She also helps clients successfully navigate crises such as recalls and unwanted Congressional or regulatory attention. In addition to her work for individual clients, Miriam serves as outside counsel to a number of key trade associations, helping them accomplish broad industry objectives by engaging with the FDA, FTC, and Congress. In recent years, Miriam has advised clients extensively regarding the federal and state legal landscapes surrounding the development and marketing of products containing cannabidiol (CBD). Chambers USA notes, Miriam is “incredibly sharp and very responsive” and a client reports, “I rely on Miriam tremendously to help me find ways forward in difficult and novel situations, and she never fails to deliver.”

As the food industry faces new challenges – including the implementation of FSMA, new food labeling requirements including bioengineering disclosures and updates to Nutrition Facts, “clean label” and consumer transparency trends, and increasing consumer fraud litigation and Prop 65 demand letters – Miriam remains at the forefront of legislative and regulatory changes and food policy and litigation trends. She draws on this deep knowledge and insight to advise clients on all aspects of food development and marketing, from product ingredient sourcing and manufacturing considerations to food labeling and marketing.

For example, Miriam helps clients develop policies and procedures to implement new FSMA requirements, and advises clients in determining whether food ingredients are generally recognized as safe (GRAS) or whether dietary ingredients require new dietary ingredient (NDI) notifications to FDA. She helps many clients convey the health benefits of their products, including by successfully petitioning the FDA for approval of a number of health claims, and helps ensure that marketing claims are appropriately phrased and adequately substantiated. Miriam also advises clients regarding the most advantageous regulatory categories for the marketing of their products – whether as conventional foods, dietary supplements, or medical foods. Partnering with Covington colleagues in international offices, Miriam helps clients solve regulatory problems across the globe.

Read more about Miriam GuggenheimEmail
Show more Show less
Photo of Deepti Kulkarni Deepti Kulkarni

Drawing from over a decade of experience working in both FDA’s Office of Chief Counsel and private practice, Deepti Kulkarni provides strategic advice to clients on a wide range of complex matters involving FDA and USDA regulatory oversight. She has played a key…

Drawing from over a decade of experience working in both FDA’s Office of Chief Counsel and private practice, Deepti Kulkarni provides strategic advice to clients on a wide range of complex matters involving FDA and USDA regulatory oversight. She has played a key role in the development and implementation of the regulatory frameworks for alternative proteins as well as bioengineered food and agriculture products.

Deepti advises companies developing and marketing animal products, foods, dietary supplements, and cosmetics at nearly every step of the product lifecycle. She also counsels clients on potential crises, such as product recalls, import refusals, and other regulatory actions.

Deepti previously served as an Associate Chief Counsel in the FDA’s Office of Chief Counsel. While at FDA, she counseled various components of FDA and HHS on a broad scope of issues related to animal products, foods, dietary supplements, and cosmetics, as well as cross-product matters involving imports and exports, advisory committees, and constitutional issues. Deepti received several awards during her time at the FDA, including the FDA Award of Merit (FDA’s highest award), Commissioner’s Special Recognition Award, and the CFSAN Director’s Special Citation Award.

Read more about Deepti KulkarniEmail
Show more Show less
Photo of Jeannie Perron Jeannie Perron

Jeannie Perron is a member of the firm’s Food and Drug Practice Group, resident in the Washington, DC Office.

In addition to being an attorney, Jeannie also holds a degree in veterinary medicine and has practiced as a veterinarian.  She specializes in food and …

Jeannie Perron is a member of the firm’s Food and Drug Practice Group, resident in the Washington, DC Office.

In addition to being an attorney, Jeannie also holds a degree in veterinary medicine and has practiced as a veterinarian.  She specializes in food and drug law, with a sub-specialty in animal food and drug law.  In this capacity, she represents companies that manufacture feed, feed ingredients, drugs, biologics and medical devices for animals, as well as clients in related industries.

Her specialties also include advising clients and providing representation on matters before the United States Department of Agriculture arising under the Animal Welfare Act.  Her clients are animal research companies, pharmaceutical companies, and animal dealers and exhibitors.

Another specialized area of practice relates to the importation of animal-derived ingredients and products.  Jeannie advises clients on USDA regulations and procedures in this area and assists clients in securing the required permits and certifications.

In addition to these other practice areas, Jeannie also advises clients in the regulation of dietary supplements, over-the-counter drugs, cosmetics for humans, and import and export of products regulated by the United States Food and Drug Administration as well as those having animal or microbially-derived ingredients regulated by USDA. 

Read more about Jeannie PerronEmail
Show more Show less
Photo of Jessica O'Connell Jessica O'Connell

Drawing from nearly twenty years of experience working at FDA and in private practice, Jessica O’Connell provides strategic advice to a broad range of companies and trade associations in navigating regulatory frameworks and engaging with food and drug regulatory bodies and Congress. She…

Drawing from nearly twenty years of experience working at FDA and in private practice, Jessica O’Connell provides strategic advice to a broad range of companies and trade associations in navigating regulatory frameworks and engaging with food and drug regulatory bodies and Congress. She works closely with clients to develop product strategies that are low-risk from both a regulatory and litigation perspective while also meeting marketing goals and objectives.

Jessica is based in our Washington, DC office and is vice chair of the Food, Drug, and Device practice group. Chambers USA reports that she “is enthusiastic, exceptionally smart and a talented lawyer who brings tremendous insight from being a regulator” and that she “knows how best to interact with the FDA in a productive and efficient way.”

She assists clients in complying with U.S. regulatory requirements for food, dietary supplements, cosmetics, and OTC drugs, and has specific expertise advising on FDA’s import and export requirements across all product categories. She also regularly counsels clients regarding potential crises, such as recalls, regulator investigations, and other unanticipated regulatory attention.

Jessica has engaged with Congress on cosmetic and drug legislative efforts and alternative protein and other food labeling requirements. She has represented clients in both FDA and FTC investigations, including negotiating consent decrees and responding to civil investigative demands, and in matters before the NAD. Jessica has specific expertise regarding the regulatory framework for new and emerging food technologies, including alternative protein ingredients and products and specialized nutrition products such as infant formula and medical foods, the marketing of cosmetics and OTC drugs, including sunscreens, Proposition 65, organic labeling, the federal and state legal landscapes surrounding the development and marketing of products containing CBD, and claim substantiation requirements, as well as manufacturing and supply chain requirements under FSMA and FDA’s implementation of MoCRA.

Jessica also has an active pro bono practice, with a particular focus on issues relating to reproductive rights and health care access.

Before joining Covington, Jessica served as Associate Chief Counsel in FDA’s Office of Chief Counsel. While at FDA, Jessica counseled various components of FDA and HHS on a broad range of food, cosmetic, and drug legal issues, including FDA’s implementation of FSMA and FDA’s work investigating foodborne illness outbreaks and related actions, including recalls and other enforcement activities. In addition, Jessica provided legal counsel to the agency and Department regarding FDA’s import and export activities for all FDA-regulated products.

Read more about Jessica O'ConnellEmail
Show more Show less